CompletedNot Applicable

Urokinase-type Plasminogen Activator Receptor and Gastroesophageal Cancer

Denmark100 participantsStarted 2019-11-18

Plain-language summary

The aim of this study is to investigate urokinase Plasminogen Activator Receptor (uPAR) microexpression in gastroesophageal cancer (adenocarcinomas) both qualitatively and semi-quantitatively and to evaluate if it offers a possibility for future imagining purposes.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥18 years old. * Patients who underwent curatively intended surgery for gastroesophageal cancer * Patients who underwent surgery after 01-01-2016. Exclusion Criteria: * Patients who applied for an exception from medical research at the "National Registry of Tissue Use." * Patients with other histological subtypes than adenocarcinoma.

What they're measuring

uPAR microexpression

Timeframe: Up to 6 months

Tumor-to-background ratio

Timeframe: Up to 6 months

Trial details

NCT IDNCT04669951

SponsorMichael Patrick Achiam

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-11-30

View on ClinicalTrials.gov More Esophagus Cancer, Adenocarcinoma trials